ZYUS Life Sciences Corporation Appoints Interim CFO; Phase 2a Topline Data Expected by Early Q4
ZYUS Life Sciences appointed John L. Knowles as interim CFO, effective Sept. 14, 2026, and expects Phase 2a UTOPIA-1 topline results by end of Q3 or early Q4 2026.Material DetailsContext by AI AnalystZYUS is a clinical-stage company progressing a cannabinoid-based pain candidate, with prior safety…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.